Biopharmaceutical Development and GMP Manufacturing August 2012

recombinant proteins (e.g., cytokines, growth factors, antibody fragments, surface antigens)

plasmid DNA

microbial vaccines (e.g., attenuated whole cell vaccines).

GMP state-of-the-art facilities for microbial production

fermentor scale up to 1,500 L

strong expertise in Escherichia coli and yeast (e.g., Pichia)

preclinical/clinical trials to market supply at a large scale.

women’s health (osteoporosis)

infectious diseases (hepatitis).

Teriparatide

IFN alpha 2a.

1,100 m² cleanroom

two filling lines built according to the latest regulatory requirements (syringe and vial/cartridge/lyophilisation line)

labeling machines

unbuilt cleanroom area 130 m² for expansion

special room for small batches.